Skip to Main Content

 

 

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Purpose

 

The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS.

Further study details as provided by Cytokinetics:


Primary Outcome Measures:

In this hypothesis-generating early Phase II study, multiple assessments of skeletal muscle function will be made without specifying a single primary endpoint, including:

1. ALS Functional Assessment
2. Maximum Grip Strength (bilateral)
3. Maximum Grip Strength Fatigability (bilateral)
4. Shoulder Extension Fatigue (bilateral)
5. Slow Vital Capacity
6. Maximal Voluntary Ventilation
7. Sniff Inspiratory Pressure
8. Maximum Voluntary Muscle Contraction of multiple bilateral muscle groups using Hand Held Dynamometry
9. Repeated Sub-Maximum Grip Strength Fatigability (bilateral)


Secondary Outcome Measures:

For further information about this study contact Katy Shaver, CCRP.

Also, please click here for more information.

 

April, 2010

 

 



ABOUT SSL CERTIFICATES

All content and works posted on this website are owned and copyrighted by The ALS Association. ©2019
Contact the Webmaster